Nghiên cứu của chúng tôi lấy mẫu người bệnh đến khám và điều trị tại Bệnh viện Ung Bướu Thành phố Hồ Chí Minh trong khoảng thời gian năm 2016 và 2017. Đây là khoảng thời gian chuyển tiếp trong việc triển khai phân loại mới của AJCC 7 và 8 tại bệnh viện. Thiết kế nghiên cứu đoàn hệ theo dõi các kết quả của quá trình điều trị cũng như các đặc điểm sinh học của bướu nguyên phát. Vì vậy chúng tôi chọn dùng một phân loại AJCC 7 để có đủ thông tin cũng như thống nhất trong nghiên cứu. Có một số nghiên cứu đoàn hệ theo dõi dài cũng đã thử phân loại theo phiên bản thứ 7 trong giai đoạn đầu và phiên bản thứ 8 trong gian đoạn sau.107,144 Tuy nhiên đa số các nghiên cứu này cũng như nghiên cứu của chúng tôi là các nghiên cứu hồi cứu. Vì vậy một số thông tin có thể sẽ không thu thập thêm được nếu muốn phân giai đoạn theo phiên bản mới. Mặc dù AJCC 8 được đánh giá là có ưu điểm hơn trong tiên lượng so với AJCC 7, tuy nhiên việc xác định độ sâu xâm lấn (DOI) hay xâm lấn vỏ bao hạch (ENE) vẫn là một vấn đề khó khăn và thách thức, không phải luôn được thực hiện do mẫu mô bệnh phẩm không đạt chuẩn về vị trí và độ sâu, nhất là trong trường hợp mẫu mô là từ sinh thiết chẩn đoán. Vì vậy, phân loại theo phiên bản thứ 8 không phải luôn thực hiện được một cách chính xác. Mặt khác, phân loại theo AJCC 8 đưa thêm vào các yếu tố mô học do đó, cần có kết quả sau phẫu thuật mà thực tế, UTHM có thể không phải luôn luôn chỉ định hoặc lựa chọn phẫu thuật. Vì vậy, không phải luôn có thể phân giai đoạn theo phiên bản thứ 8. Để nỗ lực phân giai đoạn theo phiên bản mới nhưng không phẫu thuật, một số công cụ chẩn đoán hình ảnh như chụp cắt lớp CT-Scan, MRI hoặc siêu âm để xác định DOI hoặc ENE đại thể. Tuy vậy độ nhạy và độ chuyên biệt của các phương tiện chẩn đoán này vẫn còn tranh cãi.148 DOI không thể tính cho các ca sinh thiết chẩn đoán được. Tương tự như vậy ENE cũng chỉ đánh giá được cho các ca có phẫu thuật và nạo hạch. Đánh giá theo AJCC 7 phù hợp cho giai đoạn chẩn đoán ban đầu, lập kế hoạch điều trị. AJCC 8 phù hợp để lên kế hoạch tiếp theo trong hoặc sau phẫu thuật.
143 trang |
Chia sẻ: Kim Linh 2 | Ngày: 09/11/2024 | Lượt xem: 82 | Lượt tải: 0
Bạn đang xem trước 20 trang tài liệu Luận án Biểu hiện PD-L1, đặc điểm lâm sàng và giải phẫu bệnh trong đáp ứng xạ trị và tiên lượng ung thư hốc miệng, để xem tài liệu hoàn chỉnh bạn click vào nút DOWNLOAD ở trên
26. Rivera C, Oliveira AK, Costa RAP, et al. Prognostic biomarkers in oral squamous
cell carcinoma: A systematic review. Oral Oncol. Sep 2017;72:38-47.
doi:10.1016/j.oraloncology.2017.07.003
27. Kamran SC, Berrington de Gonzalez A, Ng A, et al. Therapeutic radiation and
the potential risk of second malignancies. Cancer. Jun 15 2016;122(12):1809-21.
doi:10.1002/cncr.29841
28. Mitsudo K, Tohnai I. Cemoradiotherapy using intra-arterial infusion. Oral
Cancer: Diagnosis and Therapy. Kirita T., Omura K. Eds. Springer-Japan, Tokyo;
2015.
29. Bahadur S, Iyer S. Management of Oral Cancers. Springer; 2021.
30. Lin LH, Chang KW, Kao SY, et al. Increased Plasma Circulating Cell-Free DNA
Could Be a Potential Marker for Oral Cancer. Int J Mol Sci. Oct 24
2018;19(11)doi:10.3390/ijms19113303
31. Morikawa T, Shibahara T, Nomura T, et al. Non-Invasive Early Detection of Oral
Cancers Using Fluorescence Visualization with Optical Instruments. Cancers
(Basel). Sep 27 2020;12(10)doi:10.3390/cancers12102771
32. Cao LM, Zhong NN, Li ZZ, et al. Lymph node metastasis in oral squamous cell
carcinoma: Where we are and where we are going. Clinical and Translational
Discovery. 2023;3(4):e227.
33. El-Naggar AK, Chan JKC, Takata T, et al. The fourth edition of the head and
neck World Health Organization blue book: editors' perspectives. Hum Pathol.
Aug 2017;66:10-12. doi:10.1016/j.humpath.2017.05.014
34. Akhter M, Hossain S, Rahman QB, et al. A study on histological grading of oral
squamous cell carcinoma and its co-relationship with regional metastasis. J Oral
Maxillofac Pathol. May 2011;15(2):168-76. doi:10.4103/0973-029X.84485
35. Rahadiani N, Habiburrahman M, Handjari DR, et al. Clinicopathological
characteristics predicting advanced stage and surgical margin invasion of oral
squamous cell carcinoma: A single-center study on 10 years of cancer registry
data. Oncol Lett. Oct 2022;24(4):364. doi:10.3892/ol.2022.13484
36. Wunschel M, Neumeier M, Utpatel K, et al. Staging more important than
grading? Evaluation of malignancy grading, depth of invasion, and resection
margins in oral squamous cell carcinoma. Clin Oral Investig. Mar
2021;25(3):1169-1182. doi:10.1007/s00784-020-03421-2
37. Anneroth G, Batsakis J, Luna M. Review of the literature and a recommended
system of malignancy grading in oral squamous cell carcinomas. Scand J Dent
Res. Jun 1987;95(3):229-49. doi:10.1111/j.1600-0722.1987.tb01836.x
38. Bryne M, Koppang HS, Lilleng R, et al. Malignancy grading of the deep invasive
margins of oral squamous cell carcinomas has high prognostic value. J Pathol.
Apr 1992;166(4):375-81. doi:10.1002/path.1711660409
39. Moeckelmann N, Ebrahimi A, Tou YK, et al. Prognostic implications of the 8th
edition American Joint Committee on Cancer (AJCC) staging system in oral
cavity squamous cell carcinoma. Oral Oncol. Oct 2018;85:82-86.
doi:10.1016/j.oraloncology.2018.08.013
40. Lydiatt WM, Patel SG, O'Sullivan B, et al. Head and Neck cancers-major changes
in the American Joint Committee on cancer eighth edition cancer staging manual.
CA Cancer J Clin. Mar 2017;67(2):122-137. doi:10.3322/caac.21389
41. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging
Manual: Continuing to build a bridge from a population-based to a more
"personalized" approach to cancer staging. CA Cancer J Clin. Mar
2017;67(2):93-99. doi:10.3322/caac.21388
42. Schulz A, Meyer F, Dubrovska A, et al. Cancer Stem Cells and Radioresistance:
DNA Repair and Beyond. Cancers (Basel). Jun 21
2019;11(6)doi:10.3390/cancers11060862
43. Nguyễn Thái Hà, Nguyễn Đức Thuần. Y học hạt nhân và kỹ thuật xạ trị. NXB
Bách khoa Hà Nội; 2006.
44. Baumann R, Depping R, Delaperriere M, et al. Targeting hypoxia to overcome
radiation resistance in head & neck cancers: real challenge or clinical fairytale?
Expert review of anticancer therapy. Jul 2016;16(7):751-8.
doi:10.1080/14737140.2016.1192467
45. Perri F, Pacelli R, Della Vittoria Scarpati G, et al. Radioresistance in head and
neck squamous cell carcinoma: Biological bases and therapeutic implications.
Head Neck. May 2015;37(5):763-70. doi:10.1002/hed.23837
46. Span PN, Bussink J. The Role of Hypoxia and the Immune System in Tumor
Radioresistance. Cancers (Basel). Oct 14
2019;11(10)doi:10.3390/cancers11101555
47. Ganci F, Sacconi A, Manciocco V, et al. Radioresistance in Head and Neck
Squamous Cell Carcinoma — Possible Molecular Markers for Local Recurrence
and New Putative Therapeutic Strategies. 2015;doi:10.5772/60081
48. Dine J, Gordon R, Shames Y, et al. Immune Checkpoint Inhibitors: An
Innovation in Immunotherapy for the Treatment and Management of Patients
with Cancer. Asia Pac J Oncol Nurs. Apr-Jun 2017;4(2):127-135.
doi:10.4103/apjon.apjon_4_17
49. Fridman E, Na'ara S, Agarwal J, et al. The role of adjuvant treatment in early-
stage oral cavity squamous cell carcinoma: An international collaborative study.
Cancer. Jul 15 2018;124(14):2948-2955. doi:10.1002/cncr.31531
50. Cheng YJ, Tsai MH, Chiang CJ, et al. Adjuvant radiotherapy after curative
surgery for oral cavity squamous cell carcinoma and treatment effect of timing
and duration on outcome-A Taiwan Cancer Registry national database analysis.
Cancer Med. Jul 2018;7(7):3073-3083. doi:10.1002/cam4.1611
51. Riemenschnitter CE, Morand GB, Schouten CS, et al. Need for adjuvant
radiotherapy in oral cancer: depth of invasion rather than tumor diameter. Eur
Arch Otorhinolaryngol. Jan 2023;280(1):339-346. doi:10.1007/s00405-022-
07561-x
52. Pu YM, Yang Y, Wang YJ, et al. Postoperative radiotherapy is dispensable for
OSCC patients with micrometastases in lymph nodes. Virchows Arch. May
2018;472(5):797-805. doi:10.1007/s00428-018-2351-z
53. Hong KO, Oh KY, Shin WJ, et al. Tumor budding is associated with poor
prognosis of oral squamous cell carcinoma and histologically represents an
epithelial-mesenchymal transition process. Hum Pathol. Oct 2018;80:123-129.
doi:10.1016/j.humpath.2018.06.012
54. Alkhadar H, Macluskey M, White S, et al. Perineural invasion in oral squamous
cell carcinoma: Incidence, prognostic impact and molecular insight. J Oral
Pathol Med. Nov 2020;49(10):994-1003. doi:10.1111/jop.13069
55. Rylands J, Lowe D, Rogers SN. Outcomes by area of residence deprivation in a
cohort of oral cancer patients: Survival, health-related quality of life, and place
of death. Oral Oncol. Jan 2016;52:30-6. doi:10.1016/j.oraloncology.2015.10.017
56. Liu F, Chen F, Huang J, et al. Prospective study on factors affecting the prognosis
of oral cancer in a Chinese population. Oncotarget. Jan 17 2017;8(3):4352-4359.
doi:10.18632/oncotarget.13842
57. Gotz C, Drecoll E, Straub M, et al. Impact of HPV infection on oral squamous
cell carcinoma. Oncotarget. Nov 22 2016;7(47):76704-76712.
doi:10.18632/oncotarget.12501
58. Lyu X, Zhang M, Li G, et al. PD-1 and PD-L1 Expression Predicts
Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is
Associated with HPV Infection. J Cancer. 2019;10(4):937-948.
doi:10.7150/jca.27199
59. Schneider K, Jakobsen KK, Jensen JS, et al. Impact of p16-overexpression on
overall and progression-free survival outcomes in oral cavity squamous cell
carcinomas: A semi-national, population-based study. Oral Oncol. Dec
2020;111:105031. doi:10.1016/j.oraloncology.2020.105031
60. Lambert R, Sauvaget C, de Camargo Cancela M, et al. Epidemiology of cancer
from the oral cavity and oropharynx. Eur J Gastroenterol Hepatol. Aug
2011;23(8):633-41. doi:10.1097/MEG.0b013e3283484795
61. Ramqvist T, Mints M, Tertipis N, et al. Studies on human papillomavirus (HPV)
16 E2, E5 and E7 mRNA in HPV-positive tonsillar and base of tongue cancer in
relation to clinical outcome and immunological parameters. Oral Oncol. Dec
2015;51(12):1126-31. doi:10.1016/j.oraloncology.2015.09.007
62. Fakhry C, D'Souza G. Discussing the diagnosis of HPV-OSCC: common
questions and answers. Oral Oncol. Sep 2013;49(9):863-871.
doi:10.1016/j.oraloncology.2013.06.002
63. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-
cell apoptosis: a potential mechanism of immune evasion. Nat Med. Aug
2002;8(8):793-800. doi:10.1038/nm730
64. Lin NC, Hsu JT, Tsai KY. Difference between Female and Male Patients with
Oral Squamous Cell Carcinoma: A Single-Center Retrospective Study in Taiwan.
Int J Environ Res Public Health. Jun 4 2020;17(11)doi:10.3390/ijerph17113978
65. Satgunaseelan L, Gupta R, Madore J, et al. Programmed cell death-ligand 1
expression in oral squamous cell carcinoma is associated with an inflammatory
phenotype. Pathology. Oct 2016;48(6):574-80. doi:10.1016/j.pathol.2016.07.003
66. Maruse Y, Kawano S, Jinno T, et al. Significant association of increased PD-L1
and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous
cell carcinoma. Int J Oral Maxillofac Surg. Jul 2018;47(7):836-845.
doi:10.1016/j.ijom.2018.01.004
67. Troeltzsch M, Woodlock T, Pianka A, et al. Is There Evidence for the Presence
and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma?
Hints From an Immunohistochemical Study. J Oral Maxillofac Surg. May
2017;75(5):969-977. doi:10.1016/j.joms.2016.11.006
68. Kouketsu A, Sato I, Oikawa M, et al. Expression of immunoregulatory molecules
PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of
Japanese patients. J Craniomaxillofac Surg. Jan 2019;47(1):33-40.
doi:10.1016/j.jcms.2017.04.013
69. Oliveira-Costa JP, de Carvalho AF, da Silveira da GG, et al. Gene expression
patterns through oral squamous cell carcinoma development: PD-L1 expression
in primary tumor and circulating tumor cells. Oncotarget. Aug 28
2015;6(25):20902-20. doi:10.18632/oncotarget.3939
70. Lin YM, Sung WW, Hsieh MJ, et al. High PD-L1 Expression Correlates with
Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. PLoS One.
2015;10(11):e0142656. doi:10.1371/journal.pone.0142656
71. Straub M, Drecoll E, Pfarr N, et al. CD274/PD-L1 gene amplification and PD-
L1 protein expression are common events in squamous cell carcinoma of the oral
cavity. Oncotarget. Mar 15 2016;7(11):12024-34. doi:10.18632/oncotarget.7593
72. Chen T-C, Wu C-T, Wang C-P, et al. Associations among pretreatment tumor
necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell
carcinoma and the prognostic impact thereof. Oral Oncology. 2015;51(11):1004-
1010. doi:10.1016/j.oraloncology.2015.08.011
73. Ahn H, Yang JM, Kim H, et al. Clinicopathologic implications of the miR-
197/PD-L1 axis in oral squamous cell carcinoma. Oncotarget. Sep 12
2017;8(39):66178-66194. doi:10.18632/oncotarget.19842
74. Hirai M, Kitahara H, Kobayashi Y, et al. Regulation of PD-L1 expression in a
high-grade invasive human oral squamous cell carcinoma microenvironment. Int
J Oncol. Jan 2017;50(1):41-48. doi:10.3892/ijo.2016.3785
75. Mattox AK, Lee J, Westra WH, et al. PD-1 Expression in Head and Neck
Squamous Cell Carcinomas Derives Primarily from Functionally Anergic
CD4(+) TILs in the Presence of PD-L1(+) TAMs. Cancer Res. Nov 15
2017;77(22):6365-6374. doi:10.1158/0008-5472.CAN-16-3453
76. Kogashiwa Y, Yasuda M, Sakurai H, et al. PD-L1 Expression Confers Better
Prognosis in Locally Advanced Oral Squamous Cell Carcinoma. Anticancer Res.
Mar 2017;37(3):1417-1424. doi:10.21873/anticanres.11465
77. Stasikowska-Kanicka O, Wagrowska-Danilewicz M, Danilewicz M.
Immunohistochemical Analysis of Foxp3(+), CD4(+), CD8(+) Cell Infiltrates
and PD-L1 in Oral Squamous Cell Carcinoma. Pathol Oncol Res. Jul
2018;24(3):497-505. doi:10.1007/s12253-017-0270-y
78. De Vicente JC, Rodriguez-Santamarta T, Rodrigo JP, et al. PD-L1 Expression in
Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous
Cell Carcinoma. Cancer Epidemiol Biomarkers Prev. Mar 2019;28(3):546-554.
doi:10.1158/1055-9965.EPI-18-0779
79. Weber M, Wehrhan F, Baran C, et al. PD-L1 expression in tumor tissue and
peripheral blood of patients with oral squamous cell carcinoma. Oncotarget. Dec
22 2017;8(68):112584-112597. doi:10.18632/oncotarget.22576
80. He J, Chen XF, Xu MG, et al. Relationship of programmed death ligand-1
expression with clinicopathological features and prognosis in patients with oral
squamous cell carcinoma: A meta-analysis. Arch Oral Biol. Jun
2020;114:104717. doi:10.1016/j.archoralbio.2020.104717
81. Boustani J, Grapin M, Laurent PA, et al. The 6th R of Radiobiology: Reactivation
of Anti-Tumor Immune Response. Cancers (Basel). Jun 20
2019;11(6)doi:10.3390/cancers11060860
82. Nguyễn Chấn Hùng, Phạm Xuân Dũng, Đặng Huy Quốc Thịnh. Ức chế chốt kiểm
trong liệu pháp miễn dịch ung thư. Tạp chí Ung thư học Việt Nam. 2018;4:i-v.
83. FDA approves pembrolizumab for first-line treatment of head and neck
squamous cell carcinoma. https://www.fda.gov/drugs/resources-information-
approved-drugs/fda-approves-pembrolizumab-first-line-treatment-head-and-
neck-squamous-cell-carcinoma
84. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with
chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic
squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised,
open-label, phase 3 study. Lancet. Nov 23 2019;394(10212):1915-1928.
doi:10.1016/S0140-6736(19)32591-7
85. Punekar SR, Shum E, Grello CM, et al. Immunotherapy in non-small cell lung
cancer: Past, present, and future directions. Front Oncol. 2022;12:877594.
doi:10.3389/fonc.2022.877594
86. Fasano M, Corte CMD, Liello RD, et al. Immunotherapy for head and neck
cancer: Present and future. Crit Rev Oncol Hematol. Jun 2022;174:103679.
doi:10.1016/j.critrevonc.2022.103679
87. De Bree R, Senft A, Coca-Pelaz A, et al. Detection of Distant Metastases in Head
and Neck Cancer: Changing Landscape. Adv Ther. Feb 2018;35(2):161-172.
doi:10.1007/s12325-018-0662-8
88. Kikuchi M, Harada H, Asato R, et al. Lingual Lymph Node Metastases as a
Prognostic Factor in Oral Squamous Cell Carcinoma-A Retrospective
Multicenter Study. Medicina (Kaunas). Apr 12
2021;57(4)doi:10.3390/medicina57040374
89. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th
edition of the AJCC cancer staging manual and the future of TNM. Ann Surg
Oncol. 2010;(6):1471-1474. doi:10.1245/s10434-010-0985-. Ann Surg Oncol
2010;17(6)doi:doi:10.1245/s10434-010-0985-4
90. Kademani D, Bell RB, Bagheri S, et al. Prognostic factors in intraoral squamous
cell carcinoma: the influence of histologic grade. J Oral Maxillofac Surg. Nov
2005;63(11):1599-605. doi:10.1016/j.joms.2005.07.011
91. Yoshida S, Nagatsuka H, Nakano K, et al. Significance of PD-L1 Expression in
Tongue Cancer Development. Int J Med Sci. 2018;15(14):1723-1730.
doi:10.7150/ijms.27860
92. Cohen EEW BR, Bifulco CB, et al. . The Society for Immunotherapy of Cancer
consensus statement on immunotherapy for the treatment of squamous cell
carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019;7(1):184.
doi:10.1186/s40425-019-0662-5
93. Huang XQ, Chen X, Xie XX, et al. Co-expression of CD147 and GLUT-1
indicates radiation resistance and poor prognosis in cervical squamous cell
carcinoma. Int J Clin Exp Pathol. 2014;7(4):1651-66.
94. Weckx A, Riekert M, Grandoch A, et al. Time to recurrence and patient survival
in recurrent oral squamous cell carcinoma. Oral Oncol. Jul 2019;94:8-13.
doi:10.1016/j.oraloncology.2019.05.002
95. Nguyễn Văn Tuấn. Phân tích dữ liệu với R. NXB Tổng hợp TP HCM. 2014;Phân
tích sống còn:261-283.
96. Jawad H, Ashaari SS, O'Shea R, et al. Prognostic performance of TNM8 staging
rules in oral cavity squamous cell carcinoma. Oral Oncol. Dec 2020;111:105021.
doi:10.1016/j.oraloncology.2020.105021
97. Tirelli G, Gatto A, Boscolo Nata F, et al. Prognosis of oral cancer: a comparison
of the staging systems given in the 7th and 8th editions of the American Joint
Committee on Cancer Staging Manual. Br J Oral Maxillofac Surg. Jan
2018;56(1):8-13. doi:10.1016/j.bjoms.2017.11.009
98. Nguyễn Thị Nguyệt Ánh, Nguyễn Chấn Hùng, Nguyễn Thị Hồng, et al. Biểu hiện
keratin 4 trong biểu mô bình thường và ung thư tế bào gai niêm mạc miệng. Tạp
chí Ung thư học Việt Nam. 2017;20 (5)
99. Ferreira AK, Carvalho SH, Granville-Garcia AF, et al. Survival and prognostic
factors in patients with oral squamous cell carcinoma. Med Oral Patol Oral Cir
Bucal. May 1 2021;26(3):e387-e392. doi:10.4317/medoral.24242
100. Rikardsen OG, Bjerkli IH, Uhlin-Hansen L, et al. Clinicopathological
characteristics of oral squamous cell carcinoma in Northern Norway: a
retrospective study. BMC Oral Health. Aug 18 2014;14:103. doi:10.1186/1472-
6831-14-103
101. Kruse AL, Bredell M, Gratz KW. Oral cancer in men and women: are there
differences? Oral Maxillofac Surg. Mar 2011;15(1):51-5. doi:10.1007/s10006-
010-0253-6
102. Falaki F, Dalirsani Z, Pakfetrat A, et al. Clinical and histopathological analysis
of oral squamous cell carcinoma of young patients in Mashhad, Iran: a
retrospective study and review of literature. Med Oral Patol Oral Cir Bucal. Jul
1 2011;16(4):e473-7. doi:10.4317/medoral.16.e473
103. Patel SG, Amit M, Yen TC, et al. Lymph node density in oral cavity cancer:
results of the International Consortium for Outcomes Research. British Journal
of Cancer. 2013;109(8):2087-2095. doi:10.1038/bjc.2013.570
104. LeHew CW, Epstein JB, Kaste LM, et al. Assessing oral cancer early
detection: clarifying dentists' practices. J Public Health Dent. Spring
2010;70(2):93-100. doi:10.1111/j.1752-7325.2009.00148.x
105. Brocklehurst PR, Baker SR, Speight PM. A qualitative study examining the
experience of primary care dentists in the detection and management of
potentially malignant lesions. 1. Factors influencing detection and the decision to
refer. Br Dent J. Jan 23 2010;208(2):E3; discussion 72-3.
doi:10.1038/sj.bdj.2010.54
106. Mavedatnia D, Cuddy K, Klieb H, et al. Oral cancer screening knowledge and
practices among dental professionals at the University of Toronto. BMC Oral
Health. May 31 2023;23(1):343. doi:10.1186/s12903-023-03062-3
107. Zanoni DK, Montero PH, Migliacci JC, et al. Survival outcomes after
treatment of cancer of the oral cavity (1985-2015). Oral Oncol. Mar
2019;90:115-121. doi:10.1016/j.oraloncology.2019.02.001
108. Siriwardena BS, Rasnayaka RM, Masood Y, et al. Predictive model of oral
cancer metastasis for different cancer sites and age groups. J Investig Clin Dent.
May 2016;7(2):127-31. doi:10.1111/jicd.12145
109. Lee DS, Ramirez RJ, Lee JJ, et al. Survival of Young Versus Old Patients
With Oral Cavity Squamous Cell Carcinoma: A Meta-Analysis. Laryngoscope.
Jun 2021;131(6):1310-1319. doi:10.1002/lary.29260
110. Pires FR, Ramos AB, Oliveira JB, et al. Oral squamous cell carcinoma:
clinicopathological features from 346 cases from a single oral pathology service
during an 8-year period. J Appl Oral Sci. Sep-Oct 2013;21(5):460-7.
doi:10.1590/1679-775720130317
111. Hoda N, Bc R, Ghosh S, et al. Cervical lymph node metastasis in squamous
cell carcinoma of the buccal mucosa: a retrospective study on pattern of
involvement and clinical analysis. Med Oral Patol Oral Cir Bucal. Jan 1
2021;26(1):e84-e89. doi:10.4317/medoral.24016
112. Kreppel M, Nazarli P, Grandoch A, et al. Clinical and histopathological
staging in oral squamous cell carcinoma - Comparison of the prognostic
significance. Oral Oncol. Sep 2016;60:68-73.
doi:10.1016/j.oraloncology.2016.07.004
113. Xu B, Salama AM, Valero C, et al. The prognostic role of histologic grade,
worst pattern of invasion, and tumor budding in early oral tongue squamous cell
carcinoma: a comparative study. Virchows Arch. Sep 2021;479(3):597-606.
doi:10.1007/s00428-021-03063-z
114. Cariati P, Martinez Sahuquillo Rico A, Ferrari L, et al. Impact of histological
tumor grade on the behavior and prognosis of squamous cell carcinoma of the
oral cavity. J Stomatol Oral Maxillofac Surg. Nov 2022;123(6):e808-e813.
doi:10.1016/j.jormas.2022.07.005
115. Okada Y, Mataga I, Katagiri M, et al. An analysis of cervical lymph nodes
metastasis in oral squamous cell carcinoma. Relationship between grade of
histopathological malignancy and lymph nodes metastasis. Int J Oral Maxillofac
Surg. Jun 2003;32(3):284-8. doi:10.1054/ijom.2002.0303
116. Mai Trọng Khoa, Nguyễn Xuân Kử. Một số tiến bộ về kỹ thuật xạ trị ung thư
và ứng dụng trong lâm sàng. NXB Y học, Hà Nội; 2012.
117. Schulz D, Streller M, Piendl G, et al. Differential localization of PD-L1 and
Akt-1 involvement in radioresistant and radiosensitive cell lines of head and neck
squamous cell carcinoma. Carcinogenesis. Jul 14 2020;41(7):984-992.
doi:10.1093/carcin/bgz177
118. Knochelmann HM, Horton JD, Liu S, et al. Neoadjuvant presurgical PD-1
inhibition in oral cavity squamous cell carcinoma. Cell Rep Med. Oct 19
2021;2(10):100426. doi:10.1016/j.xcrm.2021.100426
119. Strati A, Koutsodontis G, Papaxoinis G, et al. Prognostic significance of PD-
L1 expression on circulating tumor cells in patients with head and neck squamous
cell carcinoma. Ann Oncol. Aug 1 2017;28(8):1923-1933.
doi:10.1093/annonc/mdx206
120. Cho YA YH, Lee JI, et al. . Relationship between the expressions of PD-L1
and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. . Oral
Oncol 2011;47(12):1148-1153. doi:10.1016/j.oraloncology.2011.08.007
121. Koppel C SH, Zielinski D, et al. . Optimization and validation of PD-L1
immunohistochemistry staining protocols using the antibody clone 28-8 on
different staining platforms. Mod Pathol 2018;31(11):1630-1644.
doi:10.1038/s41379-018-0071-1
122. Cheng Y, Song Z, Chen J, et al. Molecular basis, potential biomarkers, and
future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods.
Heliyon. Feb 29 2024;10(4):e25895. doi:10.1016/j.heliyon.2024.e25895
123. Schoenfeld JD, Hanna GJ, Jo VY, et al. Neoadjuvant nivolumab or nivolumab
plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2
open-label randomized clinical trial. JAMA oncology. 2020;6(10):1563-1570.
124. Greeshma L, Joseph AP, Sivakumar T, et al. Correlation of PD-1 and PD-L1
expression in oral leukoplakia and oral squamous cell carcinoma: an
immunohistochemical study. Scientific Reports. 2023;13(1):21698.
125. Steen S, Semmelmayer K, Flechtenmacher C, et al. Dynamic Up-Regulation
of PD-L1 in the Progression of Oral Squamous Cell Carcinoma. Int J Mol Sci.
Nov 16 2023;24(22)doi:10.3390/ijms242216386
126. Hu C, Tian S, Lin L, et al. Prognostic and clinicopathological significance of
PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell
carcinoma. Oral Oncology. 2020;102:104560.
127. Soopanit T, Laokulrath N, Chayopasakul V, et al. Prognostic value and
clinicopathological status of PD‐L1 expression and CD8+ TILs in oral squamous
cell cancer patients with or without traditional risk factors. Head & Neck.
2023;45(4):1017-1025.
128. Owadally W, Hurt C, Timmins H, et al. PATHOS: a phase II/III trial of risk-
stratified, reduced intensity adjuvant treatment in patients undergoing transoral
surgery for Human papillomavirus (HPV) positive oropharyngeal cancer. BMC
Cancer. Aug 27 2015;15:602. doi:10.1186/s12885-015-1598-x
129. Li CX, Tan XR, Wei W, et al. A radiobiological perspective on radioresistance
or/and radiosensitivity of head and neck squamous cell carcinoma. Rep Pract
Oncol Radiother. 2023;28(6):809-822. doi:10.5603/rpor.99355
130. Kernohan MD, Clark JR, Gao K, et al. Predicting the prognosis of oral
squamous cell carcinoma after first recurrence. Arch Otolaryngol Head Neck
Surg. Dec 2010;136(12):1235-9. doi:10.1001/archoto.2010.214
131. Kim MG, Choi YS, Youn SM, et al. Treatment outcomes and prognostic
factors in oral tongue cancer: a 20-year retrospective study at the National Cancer
Center, South Korea. J Korean Assoc Oral Maxillofac Surg. Aug 31
2022;48(4):192-200. doi:10.5125/jkaoms.2022.48.4.192
132. Lim YJ, Kong M. Population-based comparative survival analysis of surgery
with or without adjuvant radiotherapy and non-operative primary radiotherapy in
patients with early-stage oral tongue squamous cell carcinoma. Plos one.
2021;16(11):e0259384.
133. Silva LABd, Lopes MLDdS, Sá MC, et al. Histopathologic grading and its
relationship with outcome in oral tongue squamous cell carcinoma. Journal of
Oral Pathology & Medicine. 2021;50(2):183-190.
134. Amit M, Yen TC, Liao CT, et al. Improvement in survival of patients with oral
cavity squamous cell carcinoma: An international collaborative study. Cancer.
Dec 15 2013;119(24):4242-8. doi:10.1002/cncr.28357
135. Kim MJ, Ahn KM. Prognostic factors of oral squamous cell carcinoma: the
importance of recurrence and pTNM stage. Maxillofac Plast Reconstr Surg. Mar
4 2024;46(1):8. doi:10.1186/s40902-024-00410-3
136. Amit M, Tam S, Takahashi H, et al. Prognostic performance of the American
Joint Committee on Cancer 8th edition of the TNM staging system in patients
with early oral tongue cancer. Head Neck. May 2019;41(5):1270-1276.
doi:10.1002/hed.25553
137. Zhang H, Dziegielewski PT, Nguyen TJ, et al. The effects of geography on
survival in patients with oral cavity squamous cell carcinoma. Oral Oncology.
2015;51(6):578-585.
138. Vuity D, McMahon J, Takhiuddin S, et al. Is the 8th edition of the Union for
International Cancer Control staging of oral cancer good enough? Br J Oral
Maxillofac Surg. May 2018;56(4):272-277. doi:10.1016/j.bjoms.2018.01.017
139. Justesen MM, Stampe H, Jakobsen KK, et al. Impact of tumor subsite on
survival outcomes in oral squamous cell carcinoma: A retrospective cohort study
from 2000 to 2019. Oral Oncology. 2024;149:106684.
140. Lee DS, Ramirez RJ, Lee JJ, et al. Survival of young versus old patients with
oral cavity squamous cell carcinoma: a meta‐analysis. The Laryngoscope.
2021;131(6):1310-1319.
141. Hilly O, Shkedy Y, Hod R, et al. Carcinoma of the oral tongue in patients
younger than 30 years: comparison with patients older than 60 years. Oral Oncol.
Oct 2013;49(10):987-90. doi:10.1016/j.oraloncology.2013.07.005
142. Soudry E, Preis M, Hod R, et al. Squamous cell carcinoma of the oral tongue
in patients younger than 30 years: clinicopathologic features and outcome. Clin
Otolaryngol. Aug 2010;35(4):307-12. doi:10.1111/j.1749-4486.2010.02164.x
143. Santos-Silva AR, Ribeiro AC, Soubhia AM, et al. High incidences of DNA
ploidy abnormalities in tongue squamous cell carcinoma of young patients: an
international collaborative study. Histopathology. Jun 2011;58(7):1127-35.
doi:10.1111/j.1365-2559.2011.03863.x
144. Ghantous Y, Nashef A, Sidransky D, et al. Clinical and Prognostic
Significance of the Eighth Edition Oral Cancer Staging System. Cancers (Basel).
Sep 23 2022;14(19)doi:10.3390/cancers14194632
145. Shinohara S, Kikuchi M, Harada H, et al. Clinicopathological Characteristics
and Survival Outcomes of Patients with Buccal Squamous Cell Carcinoma:
Results of a Multi-Institutional Study. Medicina (Kaunas). Dec 13
2021;57(12)doi:10.3390/medicina57121361
146. Choi N, Noh Y, Lee EK, et al. Discrepancy between cTNM and pTNM staging
of oral cavity cancers and its prognostic significance. J Surg Oncol. Jun
2017;115(8):1011-1018. doi:10.1002/jso.24606
147. Erazo-Puentes MC, Sanchez-Torres A, Aguirre-Urizar JM, et al. Has the 8th
American joint committee on cancer TNM staging improved prognostic
performance in oral cancer? A systematic review. Med Oral Patol Oral Cir
Bucal. Mar 1 2024;29(2):e163-e171. doi:10.4317/medoral.25983
148. Liao L-J, Lo W-C, Hsu W-L, et al. Detection of cervical lymph node
metastasis in head and neck cancer patients with clinically N0 neck—a meta-
analysis comparing different imaging modalities. BMC cancer. 2012;12:1-7.
149. Lavaf A, Genden EM, Cesaretti JA, et al. Adjuvant radiotherapy improves
overall survival for patients with lymph node‐positive head and neck squamous
cell carcinoma. Cancer: Interdisciplinary International Journal of the American
Cancer Society. 2008;112(3):535-543.
150. Li M, Xuan G, Gu H, et al. Survival benefit associated with postoperative
PET-CT before adjuvant radiotherapy or chemoradiotherapy in patients with oral
squamous cell carcinoma. Int J Oral Maxillofac Surg. Nov 2022;51(11):1382-
1388. doi:10.1016/j.ijom.2022.03.001
151. Gartagani Z, Doumas S, Kyriakopoulou A, et al. Lymph node ratio as a
prognostic factor in neck dissection in oral cancer patients: a systematic review
and meta-analysis. Cancers. 2022;14(18):4456.
152. Almangush A, Pirinen M, Youssef O, et al. Risk stratification in oral squamous
cell carcinoma using staging of the eighth American Joint Committee on Cancer:
Systematic review and meta‐analysis. Head & Neck. 2020;42(10):3002-3017.
153. Lin N-C, Hsu J-T, Tsai K-Y. Survival and clinicopathological characteristics
of different histological grades of oral cavity squamous cell carcinoma: A single-
center retrospective study. PLoS One. 2020;15(8):e0238103.
154. Ur Rahaman SM, Ahmed Mujib B. Histopathological correlation of oral
squamous cell carcinoma among younger and older patients. J Oral Maxillofac
Pathol. May 2014;18(2):183-8. doi:10.4103/0973-029X.140734
155. Wagner VP, Webber LP, Curra M, et al. Bryne's grading system predicts poor
disease-specific survival of oral squamous cell carcinoma: a comparative study
among different histologic grading systems. Oral Surg Oral Med Oral Pathol
Oral Radiol. Jun 2017;123(6):688-696. doi:10.1016/j.oooo.2017.02.012